Welcome to our dedicated page for Elite Pharmaceuticals SEC filings (Ticker: ELTP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Following Elite Pharmaceuticals Inc.’s pipeline of controlled-release opioids and niche generics means combing through pages of DEA inventories, FDA ANDA milestones, and complex revenue-sharing agreements. If you’ve ever typed “What does Elite Pharmaceuticals report in their SEC filings?” or looked for “Elite Pharmaceuticals insider trading Form 4 transactions,” you know the challenge: disclosures scatter across multiple forms and arrive on EDGAR without warning.
Our filings hub solves that problem. Real-time alerts surface every Elite Pharmaceuticals Form 4 insider transactions filing the instant it posts, while AI-powered summaries translate the legal language inside each 8-K material event. Need the latest Elite Pharmaceuticals quarterly earnings report 10-Q filing? We pair it with an actionable earnings report filing analysis so you can spot shifts in controlled-release gross margins in seconds. Annual report 10-K simplified write-ups break down DEA compliance risk, ANDA status, and partner royalty streams—information investors track before decisive moves. The dashboard archives every form—10-K, 10-Q, 8-K, S-3, DEF 14A—so nothing slips through.
Beyond headline numbers, our platform answers natural questions like “understanding Elite Pharmaceuticals SEC documents with AI” or “Elite Pharmaceuticals proxy statement executive compensation.” You’ll see insider buying patterns, executive stock transactions Form 4 comparisons, and segment revenue charts—without scrolling through 300 pages. In short, it’s Elite Pharmaceuticals SEC filings explained simply: comprehensive coverage, AI-powered summaries, and expert context that turns regulatory data into clear, timely insight.
Elite Pharmaceuticals (ELTP) filed a Form 4 disclosing that EVP Operations Douglas Plassche sold common stock. On 10/02/2025, he executed a sale (code S) of 800,000 shares at a price of $0.624 per share. Following the transaction, he beneficially owns 3,500,000 shares, held directly.
The filing identifies the reporting person as an officer (EVP Operations) and indicates the ownership form as direct. No derivative securities transactions were reported in Table II.
FAQ
What is the current stock price of Elite Pharmaceuticals (ELTP)?
What is the market cap of Elite Pharmaceuticals (ELTP)?
